Artiva Biotherapeutics stock rises following analyst optimism

Investing.com -- Shares of Artiva Biotherapeutics Inc (NASDAQ:ARTV) climbed 2.5% as the company received positive comments from H.C. Wainwright analyst Edward White. The uptick in stock price reflects investor confidence after the analyst reiterated a Buy rating and a $20 price target for the healthcare company.

Artiva is currently focusing on the development of its lead product candidate, AlloNK, an allogeneic, off-the-shelf NK cell therapy aimed at treating autoimmune diseases. The therapy, which has already received FDA Fast Track designation for the treatment of lupus nephritis in combination with Rituxan or Gazyva, is designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion.

The company has reported that initial data from clinical trials of AlloNK in autoimmune diseases are expected in the first half of 2025. Artiva’s proprietary manufacturing process has been highlighted for its potential to produce consistent products at low costs, with the goal of reaching a cost of goods sold (COGS) of less than $1,000 per vial.

In his statement, Edward White emphasized the company’s current priorities, "Artiva anticipates initial data for AlloNK from at least one of the autoimmune trials in 1H25. The focus of the company right now is on manufacturing and getting data regarding durability and depletion of B-cells with AlloNK. The company is pursuing a variety of indications, and by YE25 we would expect to see which indications the company chooses to pursue and the reasoning for the selection of those indications. Reiterate Buy rating and $20 PT."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Artiva’s stock movement can also be attributed to the broader market’s anticipation of the upcoming data and the potential impact it could have on the company’s valuation. With a current market cap of $97 million and a stock price of $3.99, the company’s stock is responding to the optimistic outlook and the progress in its clinical trials.

Investors are keeping a close eye on Artiva as it advances through the clinical stages, with updated data in refractory/relapsed B-cell Non-Hodgkin’s Lymphoma expected later this year. The company’s strategic focus on manufacturing and data regarding AlloNK’s efficacy could position it favorably in the competitive landscape of autoimmune disease treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

ARQT: is this perennial leader facing new challenges?

With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is ARQT one of them?

Unlock ProPicks AI to find out